Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO 2019 Notebook: Lartruvo Lookback, M&A Soars, BIO Vs. ASCO

Executive Summary

News and views from day four of the BIO International Convention: Former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; emerging company M&A deals nearly double in 2018; and the ASCO effect on the 3-6 June BIO meeting.

Advertisement

Related Content

Lilly Shouldn't Return Sales From Now-Withdrawn Lartruvo, Gottlieb Says
Lartruvo Could Be A Failure Of The Drug, The Design Or The Disease
Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs
A Successful Failure? Lartruvo’s Speedy Withdrawal Sets New Bar For Accelerated Approval Drugs
‘Regulatory Risk’: A New Factor In Risk/Benefit Equation At US FDA?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS125428

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel